171 related articles for article (PubMed ID: 37152940)
1. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease.
Wang H; Zhang Y; Liu Y; Li H; Xu R; Fu H; Yan C; Qu B
Front Endocrinol (Lausanne); 2023; 14():1163682. PubMed ID: 37152940
[TBL] [Abstract][Full Text] [Related]
2. Obesity- and lipid-related indices as a predictor of obesity metabolic syndrome in a national cohort study.
Gui J; Li Y; Liu H; Guo LL; Li J; Lei Y; Li X; Sun L; Yang L; Yuan T; Wang C; Zhang D; Wei H; Li J; Liu M; Hua Y; Zhang L
Front Public Health; 2023; 11():1073824. PubMed ID: 36875382
[TBL] [Abstract][Full Text] [Related]
3. Comparison of visceral, general and central obesity indices in the prediction of metabolic syndrome in maintenance hemodialysis patients.
Zhou C; Zhan L; Yuan J; Tong X; Peng Y; Zha Y
Eat Weight Disord; 2020 Jun; 25(3):727-734. PubMed ID: 30968371
[TBL] [Abstract][Full Text] [Related]
4. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
Li H; Zhang Y; Luo H; Lin R
Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
[TBL] [Abstract][Full Text] [Related]
5. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
[TBL] [Abstract][Full Text] [Related]
6. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults.
Peng H; Pan L; Ran S; Wang M; Huang S; Zhao M; Cao Z; Yao Z; Xu L; Yang Q; Lv W
Front Endocrinol (Lausanne); 2023; 14():1083032. PubMed ID: 36742412
[TBL] [Abstract][Full Text] [Related]
7. Predicting value of five anthropometric measures in metabolic syndrome among Jiangsu Province, China.
Tian T; Zhang J; Zhu Q; Xie W; Wang Y; Dai Y
BMC Public Health; 2020 Aug; 20(1):1317. PubMed ID: 32867710
[TBL] [Abstract][Full Text] [Related]
8. Comparison of novel visceral obesity indexes with traditional obesity measurements in predicting of metabolically unhealthy nonobese phenotype in hemodialysis patients.
Zhou C; Peng Y; Jiang W; Yuan J; Zha Y
BMC Endocr Disord; 2021 Dec; 21(1):244. PubMed ID: 34923974
[TBL] [Abstract][Full Text] [Related]
9. The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease.
Kuang M; Sheng G; Hu C; Lu S; Peng N; Zou Y
Lipids Health Dis; 2022 Oct; 21(1):104. PubMed ID: 36266655
[TBL] [Abstract][Full Text] [Related]
10. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults.
Duan S; Yang D; Xia H; Ren Z; Chen J; Yao S
Front Endocrinol (Lausanne); 2022; 13():1004855. PubMed ID: 36187093
[TBL] [Abstract][Full Text] [Related]
12. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.
Duan SJ; Ren ZY; Zheng T; Peng HY; Niu ZH; Xia H; Chen JL; Zhou YC; Wang RR; Yao SK
World J Gastroenterol; 2022 Sep; 28(36):5364-5379. PubMed ID: 36185625
[TBL] [Abstract][Full Text] [Related]
13. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
[TBL] [Abstract][Full Text] [Related]
14. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
Chen J; Mao X; Deng M; Luo G
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
[TBL] [Abstract][Full Text] [Related]
15. Anthropometric parameter that best predict metabolic syndrome in South west Nigeria.
Adejumo EN; Adejumo AO; Azenabor A; Ekun AO; Enitan SS; Adebola OK; Ogundahunsi OA
Diabetes Metab Syndr; 2019; 13(1):48-54. PubMed ID: 30641748
[TBL] [Abstract][Full Text] [Related]
16. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population.
Lin IT; Lee MY; Wang CW; Wu DW; Chen SC
Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498329
[TBL] [Abstract][Full Text] [Related]
17. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters.
Xue Y; Xu J; Li M; Gao Y
Front Endocrinol (Lausanne); 2022; 13():951689. PubMed ID: 36120429
[TBL] [Abstract][Full Text] [Related]
18. Predicting hypertension by obesity- and lipid-related indices in mid-aged and elderly Chinese: a nationwide cohort study from the China Health and Retirement Longitudinal Study.
Li Y; Gui J; Zhang X; Wang Y; Mei Y; Yang X; Liu H; Guo LL; Li J; Lei Y; Li X; Sun L; Yang L; Yuan T; Wang C; Zhang D; Wei H; Li J; Liu M; Hua Y; Zhang L
BMC Cardiovasc Disord; 2023 Apr; 23(1):201. PubMed ID: 37081416
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort.
Zeng J; Jin Q; Yang J; Yang RX; Zhang RN; Zhao J; Fan JG
Hepatol Int; 2023 Dec; 17(6):1416-1428. PubMed ID: 37728728
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.
Okada A; Yamada G; Kimura T; Hagiwara Y; Yamaguchi S; Kurakawa KI; Nangaku M; Yamauchi T; Matsuyama Y; Kadowaki T
J Diabetes Investig; 2023 Mar; 14(3):463-478. PubMed ID: 36566480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
